Clinical Trials

Text Size A A

E-Mail to a Friend



secret  Click to Play Audio


Send To Friend

SCCA Clinical Studies: Lung Cancer

SCCA was formed, in part, to bring promising new treatments to patients faster. For lung cancer patients this means more treatment options are available at SCCA than might be found elsewhere, including participation in one of many ongoing clinical trials conducted at SCCA and its parent organizations, Fred Hutchinson Cancer Research Center and UW Medicine.

Click here to view a list of all the lung cancer trials at SCCA or search for a trial below.

Our current high priority trials include:

  • Erlotinib + OSI-906 for NSCLC (UW10054)
    A Randomized, Double-Blind, Phase 2 Study of Erlotinib (Tarceva®) in Combination With OSI-906 or Placebo in Chemonaive Patients With Advanced NSCLC With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene
  • PF-00299804 vs. Erlotinib for Advanced Non-Small Cell Lung Cancer (UW1108)
    A Randomized, Double-Blind Phase 3 Study Of PF-00299804, A Pan-Her Inhibitor, Vs. Erlotinib For The Treatment Of Advanced Non-Small Cell Lung Cancer Following Progression After, Or Intolerance To, At Least One Prior Chemotherapy